QC
CADL icon

Quent Capital’s Candel Therapeutics CADL Stock Holding History

Quent Capital’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-182
Closed -$246 – 1328
2023
Q1 		$246 Hold
182
– – ﹤0.01% 1285
2022
Q4 		$326 Hold
182
– – ﹤0.01% 1267
2022
Q3 		$1K Hold
182
– – ﹤0.01% 1141
2022
Q2 		$1K Hold
182
– – ﹤0.01% 1089
2022
Q1 		$1K Buy
+182
New +$904 ﹤0.01% 1183

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BWM
Baystate Wealth Management Boston, Massachusetts $1.36B AUM 15.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Quent Capital's CADL Position: Q2 2023 in Review

Quent Capital sold out of Candel Therapeutics (CADL) in Q2 2023, closing a stake of 182 shares — an estimated $246 sold.

Quent Capital first reported a position in CADL in Q1 2022 and held it in 5 quarters. The position peaked at $1K in Q3 2022. 20 funds tracked by Wall St. Rank hold CADL as of Q2 2023.

  • Quent Capital reported no remaining Candel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Quent Capital sold 182 Candel Therapeutics shares in Q2 2023, an estimated $246.
  • Quent Capital first reported a position in Candel Therapeutics in Q1 2022 and held it in 5 quarters.
  • Quent Capital's Candel Therapeutics position peaked at $1K in Q3 2022.
  • 20 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2023.

Based on Quent Capital's 13F filing for Q2 2023, filed 10 Jul 2023.